Treamid Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
2ndary - Private
Treamid Therapeutics General Information
Description
Developer of chemical entities designed to treat inflammatory respiratory and endocrine diseases. The company investigates the mode and mechanism of action of their patent-protected chemical substances regarding their therapeutic potential in the treatment of airway diseases, enabling patients to get treated by innovative and easily accessible medications.
Contact Information
Website
www.treamid.comCorporate Office
- Robert-Rössle-Straße 10
- Haus 80 (Otto-Warburg-Haus)
- 13125 Berlin
- Germany
Corporate Office
- Robert-Rössle-Straße 10
- Haus 80 (Otto-Warburg-Haus)
- 13125 Berlin
- Germany
Treamid Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | 01-Dec-2020 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC | 04-Jan-2017 | Completed | Startup |
Treamid Therapeutics Patents
Treamid Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4818160-A1 | Salts and salt hydrates of n,n'-bis[2-(1h-imidazol-4-yl)ethyl] oxalamide for the treatment of cough and fibrosis of lungs, liver, kidneys, pancreas, and heart | Pending | 02-Apr-2025 | ||
| WO-2026210001-A1 | Salts and salt hydrates of n,n'-bis[2-(1h-imidazol-4-yl)ethyl]oxalamide for the treatment of diseases accompanied by fibrotic formations and/or cough | Pending | 02-Apr-2025 | ||
| WO-2023177328-A1 | Bisamide derivative of dicarboxylic acid for use in restoring the external respiratory function after coronavirus infection | Inactive | 17-Mar-2022 | ||
| AU-2016266439-A1 | Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function | Active | 27-May-2015 | ||
| AU-2016266439-B2 | Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function | Active | 27-May-2015 | A61K31/4164 |
Treamid Therapeutics Signals
Treamid Therapeutics FAQs
-
When was Treamid Therapeutics founded?
Treamid Therapeutics was founded in 2016.
-
Where is Treamid Therapeutics headquartered?
Treamid Therapeutics is headquartered in Berlin, Germany.
-
What is the size of Treamid Therapeutics?
Treamid Therapeutics has 3 total employees.
-
What industry is Treamid Therapeutics in?
Treamid Therapeutics’s primary industry is Drug Discovery.
-
Is Treamid Therapeutics a private or public company?
Treamid Therapeutics is a Private company.
-
What is Treamid Therapeutics’s current revenue?
The current revenue for Treamid Therapeutics is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process